Record PAT masks footwear headwinds; FY27 guidance at risk
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Reaffirmed FY27 PAT ₹200–220 Cr from prior call; Q1 delivered +33.8% PAT, validating near-term momentum but not de-risking full-year target.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 PAT growth of 33.8% is robust, but footwear headwinds (₹6 Cr impact) and a tight path to ₹200 Cr FY27 guidance (Q1 run-rate ~₹171 Cr annualized) create execution risk. Reaffirmed guidance signals confidence but leaves limited margin for error on H2 footwear recovery and capex execution.
₹1201.1 Cr
Revenue · +20.7% YoY₹42.8 Cr
Reported PAT · +34.8% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Delivered highest ever quarterly PAT with 33% growth
MET₹42.8 Cr PAT confirms 33.8% YoY growth; accurate
Total income ₹1,207 Cr with 18% growth
OVERSTATEDDelivered revenue ₹1,201 Cr shows 20.7% YoY growth; management understated growth rate
Footwear business faced ₹6 Cr cost pressure this quarter
MET₹3 Cr wage impact + materials/freight; specific quantification provided, supportable
Order book full H2 FY27 for footwear with new customer wins
METCapacity utilization expected 80–90% from August onwards; stated multiple times without contradiction
Reaffirm FY27 PAT guidance ₹200–220 Cr (34–48% growth over FY26)
MixedQ1 PAT ₹42.8 Cr annualizes to ~₹171 Cr; guidance implies improving H2 and footwear recovery. Tight margin of safety.
Earnings quality
What changed since the last call
Footwear headwind quantified at ₹6 Cr
DowngradePrior call had no specific footwear drag figure; Q1 now shows Middle East logistics crisis + 30% Haryana wage hike created ₹6 Cr EBIT hit. Recovery dependent on customer negotiations H2.
HPC demand materially improved
UpgradeManagement now says 'materially changed' vs 3 months ago; liquid home care category showing double-digit volume growth; new capacity ₹50 Cr at Lucknow reflects confidence shift.
Capex plan accelerated to ~₹500 Cr FY27
UpgradePrior FY26 capex was record; FY27 now set to exceed it. ₹340 Cr new projects signed; breakup: ₹210 Cr F&B, ₹80 Cr ice cream, ₹50 Cr HPC. Signals aggressive growth bet.
Project pipeline visibility shared: ₹1,000 Cr in discussion
NewPrior call did not disclose pipeline depth; Q1 call now reveals ₹1,000 Cr of inquiries in various stages. Conversion rate not specified; execution risk acknowledged.
FY27 PAT guidance maintained ₹200–220 Cr
NeutralSame range as prior call; no change. Reaffirmation amid footwear pressure signals confidence in H2 recovery, but no upgrade despite Q1 +33.8% growth.
The Q&A
Analysts pressed hard on footwear margin path, capex execution risk, and tight FY27 guidance math. Management held firm on recovery narrative, detailing customer negotiations underway and H2 order book fill. On capacity utilization disclosure, management deflected to protect customer confidentiality (dedicated factories). Overall, confident tone but measured—management did not overstate upside.
Footwear cost pass-through — Abneesh Roy, Nuvama
AnsweredYes, most contracts have pass-through. Footwear is exception due to 6–8 month fixed pricing model. Q1 hit ₹6 Cr; starting this quarter, customers agreeing to cost absorption for upcoming seasons.
Capex allocation by segment — Abneesh Roy, Nuvama
AnsweredF&B ₹210 Cr (Coimbatore, Mysore, Goa, Aurangabad, Hyderabad), Ice Cream ₹80 Cr Panipat, HPC ₹50 Cr Lucknow. All at record demand levels.
Regulatory food claim risk — Abneesh Roy, Nuvama
AnsweredNo risk. Brand bears label claim liability, not us. FSSAI cleanup will benefit organized contract manufacturers long-term by consolidating market.
Footwear capacity utilization and new customers — Surbhi, Bellwether Capital
AnsweredQ1 was low due to freight/material disruptions. From August, 80–90% utilization expected. Full order book from mix of existing customers (increased orders) and new multinational wins. South units now have full books after learning curve.
Footwear employee cost quantum — Surbhi, Bellwether Capital
Answered35–40% of total employee cost. Footwear has ~5,000 people; wage increase impact ₹3 Cr for quarter.
Beverage capex ROCE assumptions — Surbhi, Bellwether Capital
AnsweredMost projects are anchor-tenant basis (customer-underwritten), so utilization should not be an issue. EBIT will increase 18% on capex investment; maintain 1:1 debt-equity so some interest outflow.
Footwear raw material cost mechanics — Abhishek Mathur, Systematix
AnsweredPrices & RM rates fixed 6–12 months in advance for shoe season. Brands do not change finished goods prices if RM costs spike. Currently 50–60% polymer price increase; negotiating customer cost-share for next season.
Customer perception evolution — Akhil Parekh, 360 ONE Capital
AnsweredHFL defined FMCG contract manufacturing in India. Now seen as execution partner who sustains through crisis (Silvassa flood), executes at scale across geographies, and has domain expertise via 5 BUs with seasoned CEOs.
Wallet share and pricing power with top customers — Akhil Parekh, 360 ONE Capital
PartialAfter ₹500 Cr capex last year, already signed ₹500 Cr new projects this year. Pipeline ₹1,000 Cr. Beginning to mirror a national airline for FMCG—if we shut down for days, FMCG industry would face trouble. Pricing power improving with scale and diversification.
Shoe business path to profitability — Mayur Parkeria, Wealth Managers India
AnsweredMarket dynamics changing. Positioned better in last 2 years; last quarter operational team delivered despite uncertainty. Customer confidence building; translated into order increases and new logos. BIS certification helped, but execution & team performance is the core driver.
HPC category recovery acceleration — Mayur Parkeria, Wealth Managers India
AnsweredMaterially changed. Record capex FY27 (even higher than FY26), ₹1,000 Cr pipeline, higher traction in HPC. Still hesitant to be bullish due to macro uncertainty, but definitely more bullish on HPC than 3 months ago.
Gross block to revenue growth dissonance — Rahul, Ambit Investment Advisors
AnsweredGST inversion and customer RM supply methodology: customers supply RM/PM, we recognize only conversion cost. Result: disproportionate EBITDA/PAT growth vs revenue. Gross block grows faster as capex cycles through. Will continue due to structural shift.
FY27 guidance reaffirmation amid footwear drag — Virat Pansuriya, SkyRidge Wealth
DodgedToo early to revise. Footwear recovery expected H2. Come back in couple of quarters if revision needed. Right now, reaffirming same range.
Guidance
No specific FY27 revenue target disclosed; only PAT guidance given
LowManagement focuses capex & orders announced; revenue not quantified. Q1 tracking ₹1,201 Cr; annualized run-rate ~₹4,800 Cr but seasonal variation (H2 peaks on ice cream & beverages).
OPM expected to improve H2 as footwear recovery kicks in; NPM stable around 3.5% baseline
MediumQ1 footwear drag ₹6 Cr on EBIT will ease in H2. Management expects margin recovery through cost pass-through and operational efficiency. GST inversion tailwind on PAT vs revenue comparison noted.
FY27 capex ~₹490–500 Cr (₹340 Cr new + ₹150 Cr carryforward); higher than record FY26
HighBoard-approved ₹340 Cr new projects; carryforward quantified. Breakup disclosed: ₹210 Cr F&B (5 units), ₹80 Cr ice cream Panipat, ₹50 Cr HPC Lucknow. All customer-anchored.
Risks the call surfaced
Footwear margin recovery
High₹6 Cr Q1 EBIT drag from wage hike & freight. Management expects recovery via customer cost pass-through H2, but past delays seen on new logos. If footwear does not recover, FY27 PAT guidance (₹200–220 Cr) at risk.
FY27 PAT guidance tightness
HighQ1 ₹42.8 Cr annualizes to ~₹171 Cr; guidance floor ₹200 Cr requires 16.5% H2 step-up. Dependent on footwear recovery, ice cream/beverage seasonal strength, and capex ramp. If H2 is only ₹46 Cr per quarter, guidance will miss.
Geopolitical supply chain disruption
MediumMiddle East crisis has spiked freight 4x and polymer prices +50–60%. Silvassa facility experienced record rainfall (flood). Machine imported from China stuck on Iranian ship for 2.5 months. Shoe business most exposed; other divisions have pass-through but lag.
Capex execution and ROCE delivery
Medium₹500 Cr FY27 capex is aggressive (>15% of expected PAT ₹200 Cr). Most projects are anchor-tenant basis (customer-underwritten), reducing utilization risk but increasing customer concentration risk. Execution delays or customer volume shortfalls would compress ROCE below 18% threshold.
Customer concentration risk
MediumManagement did not disclose top 5 customer concentration %. Shoe business is new (2-year turnaround); ice cream & beverages are newer growth engines. Loss of a single anchor customer in any division could materially impact that division's profitability.
Management
Score 7/10. Clear on operational updates and cost breakdown. Transparent on footwear headwinds (₹6 Cr quantified). Careful on customer/pricing details (cites confidentiality). Articulately frames long-term positioning but vague on multi-year targets. Track record solid: FY26 record capex ~₹500 Cr followed by ₹500 Cr new project signings FY27. Silvassa flood recovery within 1 week. Footwear turnaround into profitability claimed but H2 outcome pending. Execution on capex ramps will define next 2 years.
1 · Q2–Q3 FY27 (Oct–Dec 2026)
Footwear order book fill and H2 capacity ramp-up; new customer traction recovery to offset wage/material headwinds
2 · Q4 FY27 (Jan–Mar 2027)
Ice cream & beverages seasonal demand peak; new capacity commissioning (Silvassa brownfield, Lucknow greenfield)
3 · FY28 planning (Apr–Jun 2027)
Capex payoff: ₹500 Cr FY27 investment begins materializing as revenue lift; project pipeline (₹1,000 Cr) converts to confirmed orders
Reaffirmed guidance signals confidence but leaves limited margin for error on H2 footwear recovery and capex execution.
Record PAT Masks a Tight Path to Full-Year Guidance
The quarter delivered highest-ever quarterly profit of ₹42.8 Cr and 34.8% YoY growth, yet the stock fell 2% on day 1. The mathematics of the full-year target reveals why the market is skeptical.
₹42.8 Cr
Highest ever quarterly; +34.8% YoY
~₹171 Cr
Against ₹200 Cr guidance floor
~₹29 Cr
Requires 16.5% H2 step-up
Hindustan Foods reported its highest-ever quarterly profit—a 34.8% year-on-year jump to ₹42.8 Cr—yet the stock closed down 2% on day 1 of the announcement, faded further by day 5. This disconnect is not irrational. When you annualize Q1 (₹42.8 Cr × 4), it arrives at ~₹171 Cr, a number that sits ₹29 Cr below the ₹200 Cr floor of the company's own FY27 PAT guidance range. To meet that floor and deliver the promised 34–48% full-year growth, the second half must step up by 16.5% from Q1—on the back of an unverified footwear margin recovery and capex ramp execution with no margin for error. The market's skepticism is grounded.
What the numbers actually say
Q1 delivered ₹1,201 Cr revenue (+20.7% YoY, outpacing management's own guidance of 18% growth) and net profit of ₹42.8 Cr at 3.5% NPM. EBITDA grew a healthy 26% YoY. But operating margin compressed to 8.3% from prior quarters, a signal that cost inflation and one-time headwinds are eating into profitability. Specifically, footwear took a ₹6 Cr EBIT hit this quarter—₹3 Cr from a Haryana wage hike and the balance from Middle East logistics crisis (freight 4x, raw material polymers +50–60%). This is not a structural problem; management expects recovery starting H2 as customer cost-sharing agreements kick in and order books fill to 80–90% utilization.
Highest-ever quarterly PAT with 33% growth
₹42.8 Cr confirms 33.8% YoY growth; accurate
Supported
Total income ₹1,207 Cr with 18% growth
Delivered ₹1,201 Cr with 20.7% YoY growth; management understated actual growth
Overstated
Footwear business faced ₹6 Cr cost pressure
₹3 Cr wage impact + materials/freight; specific quantification matches
Supported
Order book full H2 FY27 for footwear with new customer wins
Capacity utilization expected 80–90% from August onwards; stated consistently in Q&A
Supported
Reaffirm FY27 PAT guidance ₹200–220 Cr
Q1 ₹42.8 Cr annualizes to ~₹171 Cr; guidance requires 16.5% H2 lift, dependent on footwear recovery
Mixed (tight margin of safety)
What changed on this call
HPC demand materially improved vs. 3 months ago
Capex plan accelerated to ~₹500 Cr FY27 (₹340 Cr new + ₹150 Cr carryforward)
Footwear headwind quantified at ₹6 Cr (prior call had no specific figure)
Project pipeline visibility disclosed: ₹1,000 Cr in discussion (new metric)
Footwear business now positioned as recovery-ready (vs. long-turnaround narrative prior)
FY27 PAT guidance maintained, not upgraded despite 34.8% Q1 growth
The positives: HPC (Home & Personal Care) demand has shifted materially in management's view—from cautious three months ago to materially improved now—driving a ₹50 Cr new capex commitment at Lucknow. Footwear, which consumed management commentary on prior calls as a turnaround story, is now described as recovery-ready with full order books and customer cost-share agreements starting this quarter. The negatives: despite Q1 delivering the highest-ever quarterly PAT and 34.8% growth, management did not raise the full-year PAT guidance (still ₹200–220 Cr). This silence on the upside is the real tell. It signals that management sees the H2 footwear recovery as margin-neutral (absorbing the ₹6 Cr offset), not accretive. And it means capex ramp execution risk is real—the ₹500 Cr investment must come in on time and at target ROCE.
The market's own verdict
On the day of the result announcement, the stock opened and closed down 2.0%. By day 3, it was off 1.76%; by day 5, -1.85%. The negative drift despite a headline-grabbing profit number is the market's honest assessment: the math is tight, and H2 execution is binary. This happened despite a bullish price trend (the stock sits just 1.5% below its all-time high of ₹600.4 and is up 33.8% from its 52-week low of ₹442). Ownership flows are flat: FII added 4 basis points to 5.86%, DII trimmed 40 basis points to 14.65%, and promoters added 54 basis points to 61.85%. Institutions are neither accumulating nor fleeing; they are waiting to see if Q1 momentum holds or if footwear headwinds resurface in Q2.
Bull and bear case
Highest-ever quarterly PAT (₹42.8 Cr); validates organic growth momentum
EBITDA growth +26% YoY; operating leverage intact
Diversified 5-BU platform reducing single-segment risk
Capex anchored by customers (anchor-tenant model); utilization risk mitigated
Pricing power improving with scale; ₹1,000 Cr pipeline signals multi-year runway
Footwear margin recovery unverified; dependent on customer cost-share negotiations
Q1 run-rate requires 16.5% H2 step-up to hit ₹200 Cr guidance floor; no margin for error
Capex ₹500 Cr is material (~250% of guidance midpoint PAT); execution delays compress FY28+ growth
GST duty inversion cash-flow drag ongoing; RM-supply model inflates PAT vs. revenue growth
Customer concentration undisclosed; new wins in footwear/ice cream are recent and unproven
Risks, ranked by impact to a holder
Footwear H2 margin recovery fails to materialize
HighIf customer cost-share negotiations stall or customer demand softens, the ₹6 Cr Q1 drag persists into H2. With Q1 already at ₹42.8 Cr, a flat H2 would drop FY27 PAT to ~₹180 Cr, below guidance floor. Market would cut multiples on execution failure.
FY27 PAT guidance math is too tight
HighQ1 ₹171 Cr run-rate vs. ₹200 Cr target leaves no room for seasonality miss, macro softness, or capex ramp delays. If H2 only averages ₹45 Cr/quarter (vs. required ₹57 Cr), guidance misses. Management will face pressure to revise downward.
Geopolitical supply chain remains disrupted
MediumMiddle East crisis has spiked freight 4x and polymer costs +50–60%. Silvassa facility experienced record rainfall. Footwear (50% imported RM) is most exposed. If crisis persists or escalates, customer cost-share agreements unravel and margin recovery slips.
Capex execution slips or ROCE falls short of 18% target
Medium₹500 Cr FY27 capex is ambitious (~250% of PAT guidance midpoint). Most projects are anchor-tenant basis (customer-underwritten), but delays in commissioning or lower-than-expected utilization would compress FY28+ growth. ₹1,000 Cr pipeline conversion rate is unspecified; execution risk is high.
Customer concentration in footwear, ice cream, beverages undisclosed
MediumNo top-5 customer breakdown provided. Footwear and ice cream are newer growth engines with recent customer wins. Loss of a single anchor customer would derail divisional growth. Risk is structurally present but masked by aggregate metrics.
What to watch next (the Q2 settlement points)
1 · Footwear margin recovery: cost pass-through and capacity utilization
Q2 earnings should show footwear EBIT recovering from the Q1 ₹6 Cr drag. Watch for: (a) management commentary on customer cost-share agreement adoption (how many % of orders), (b) capacity utilization (did it hit the promised 80–90% from August?), (c) sequential footwear EBIT (did it improve vs. Q1?). This is the hinge of the guidance case.
2 · Q2 reported PAT and sequential trajectory
Q1 was ₹42.8 Cr. H2 needs to average ₹57.1 Cr/quarter to hit ₹200 Cr FY27 floor. Q2 (July–Sept) is a seasonally softer quarter for ice cream and beverages, so ₹48–52 Cr would be on-track. If it's ₹45 Cr or lower, the guidance path fractures and a revision looms.
3 · Capex ramp-out and project commissioning schedule
Management committed ₹500 Cr FY27 capex (₹340 Cr new + ₹150 Cr carryforward). Q2 guidance should clarify: (a) how much capex has been drawn/committed to date, (b) timeline for commissioning of Silvassa brownfield, Lucknow greenfield, Panipat ice cream, and F&B units (target is Jan–Mar 2027 per the call), (c) early utilization trends at recently commissioned Panipat and Aurangabad facilities. Delays here defer revenue into FY28 and would lower FY27 PAT.
The honest read
Hindustan Foods is executing well. The ₹42.8 Cr Q1 PAT is genuine—diversified, profitable, and growing at 34.8% YoY against a backdrop of macro uncertainty and footwear headwinds. The 5-BU platform is maturing; HPC is strengthening; capex is customer-anchored. But the company is not being rewarded with multiple expansion or even a flat entry—the stock sold off day 1 despite a record result. Why? Because the market reads the math correctly: FY27 guidance of ₹200–220 Cr is achievable, but only if three independent variables all break the company's way: footwear margin recovery (unverified), ice cream/beverage seasonal strength (not yet confirmed in Q2), and capex execution (no track record on ₹500 Cr spend at this velocity). If any one falters, the full-year target slips. This is not a condemnation of management's credibility—it is an honest assessment of the risk-reward at current levels.
The bull case is straightforward: Q1 validates the earnings power of the diversified platform; footwear recovery is underway (order book full, cost pass-through starting); capex is being deployed at record pace into a ₹1,000 Cr pipeline of customer inquiries. If execution holds, the stock re-rates materially. The bear case is equally clear: Q1 ₹171 Cr run-rate + 16.5% H2 lift is a narrow path; footwear cost-share agreements are still in negotiation (not guaranteed); capex delays and ROCE shortfalls would compound. The street's skepticism (2% day-1 decline, flat ownership flows) reflects a fair reading of these trade-offs.
Rating: Hold. The quarter is strong, but the full-year guidance is tight. Watch Q2 for evidence of footwear cost pass-through adoption, sequential PAT trajectory, and capex ramp confirmation. If those three metrics move positively, a re-rating is warranted. If they stumble, a guidance revision is incoming. Until then, the stock is priced fairly for the execution risk embedded in the ₹200–220 Cr target. The single number to track from here is Q2 footwear EBIT—it will determine whether management's H2 recovery narrative holds water or requires revision.
Hindustan Foods Q1 FY27: consolidated PAT +33% YoY to ₹42.8 Cr, margins expand, guidance held
PAT +32.75% YoY · revenue +17.9% · margins expanding · inline vs street
₹1,201.08 Cr
+17.9% YoY
₹42.76 Cr
+32.75% YoY
3.54%
+0.4pp YoY
₹3.53
Hindustan Foods posted consolidated revenue of ₹1,201.08 Cr (+17.9% YoY, +7.6% QoQ) and PAT of ₹42.76 Cr (+32.8% YoY on the filing's restated ₹32.21 Cr base, +2.9% QoQ) for Q1 FY27, with EPS at ₹3.53 versus ₹2.70 a year ago. NPM improved to 3.56% from 3.16% YoY, though it eased from 3.72% in Q4 FY26. Neither this quarter nor the year-ago quarter carried an exceptional item, so the YoY comparison is clean at the P&L level — but part of the growth is inorganic: the quarter includes the newly acquired Ultra Beauty Care manufacturing facility at Aurangabad (₹21.81 Cr consideration, acquired April 1, 2026), and the company explicitly flags Q1 FY27 as not comparable to prior periods on this count. Standalone PAT of ₹40.81 Cr (+32.2% YoY) tracks the consolidated growth closely, with no material divergence between the two.
Q1 FY-2027 vs prior quarters
Operating margin was roughly 8.3-8.4% this quarter versus about 7.9-8.0% a year ago (modest YoY expansion) but down from the 8.9-9.3% band in Q4 FY26 — cost of materials consumed rose to ₹964.32 Cr (80% of revenue) and manufacturing/operating costs to ₹72.84 Cr, while finance costs (₹23.40 Cr) and depreciation (₹26.18 Cr) both stepped up as newly added capacity, including the Aurangabad facility, comes onstream and utilization is still ramping.
The stock went into the print at ₹586.85, up 8.1% over the past month of trading.
For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 5 consecutive quarters; revenue is at a 6-quarter high.
Management reiterated confidence in sustaining profitable growth and delivering FY27 PAT guidance in the range of INR200 crores to INR220 crores, representing significant year-on-year growth. They expect improving utilization across newly commissioned capacities, rising operational leverage, and healthy execution momen
— This quarter: met
Management's press release title itself frames the quarter as 'Reaffirms Guidance' — the FY27 PAT guidance of ₹200-220 Cr given on the May 2026 concall stands, and Q1's ₹42.76 Cr consolidated PAT is about 19-21% of that full-year range, consistent with a back-half-loaded ramp as utilization improves through the year, as management had previously indicated. No quarter-specific street consensus was found; full-year FY27 analyst estimates (Trendlyne) point to roughly 20.5% revenue growth and 35.1% profit growth, against which Q1's 17.9% YoY revenue growth and 32.8% adjusted PAT growth run broadly in line, slightly behind on revenue. Management's own commentary attributes the print to 'robust execution and the continued strength of our diversified manufacturing platform,' tying it to capacity investments across beverages, ice cream and home & personal care — consistent with the quarter's acquisition-led capacity addition.
W1
Silvassa flood damage quantification and insurance recovery in Q2 FY27 disclosures
W2
FY27 PAT guidance of ₹200-220 Cr requires the remaining three quarters to deliver ~₹157-177 Cr combined versus Q1's ₹42.76 Cr
W3
Whether OPM recovers from the sequential dip (~8.3-8.4% vs ~8.9-9.3% in Q4 FY26) as newly added capacity utilization improves, per management's stated driver
No exceptional items in Q1 FY27 or Q1 FY26 (clean YoY base); Q4 FY26 carried a ₹1.07 Cr (consol.) exceptional item. Q1 FY26 comparative in this filing (₹32.21 Cr PAT) is restated upward from our on-file ₹31.73 Cr to reflect two NCLT-approved schemes (Avalon Cosmetics Nashik-unit merger, Vanity Case India amalgamation) effective Mar 31, 2026. Q1 FY27 also includes the newly acquired Ultra Beauty Care Aurangabad facility (acquired Apr 1, 2026); company states the quarter is 'not comparable' with prior periods on this count. Consolidated includes a small share of associate loss (₹0.09 Cr).